To successfully defend legal challenges againstcompensation committee decisions, biopharmaceutical companies must make greater efforts to obtain the necessary approvals from stockholders. Healthcare industry partners Doreen Lilienfeld, and Mark Kessel co-authored a letter to the editor on this subject that was published in Nature Biotechnology. According to the authors, biopharmaceutical companies will ignore the Delaware director compensation cases at their own peril.
View full article, Delaware Director Compensation Cases
